Amphitryon

Amphitryon is a pre-clinical stage biotechnology company focused on developing next-generation T-cell engagers (TCEs) for the treatment of solid tumors. The company aims to overcome the limitations of current TCE therapies, such as cytokine release syndrome (CRS) and poor penetration into solid tumor microenvironments. By utilizing a proprietary platform, Amphitryon designs molecules with optimized binding kinetics and tumor-selective activation. The leadership team includes industry veterans with significant experience in cell therapy and oncology drug development, including CEO Peter Emtage and BiTE pioneer Patrick Baeuerle. Headquartered in Waltham, Massachusetts, the company is backed by prominent life science investors including Forbion and F-Prime Capital.